



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

July 12, 2022

Bo Karmark  
Chief Financial Officer  
Evaxion Biotech A/S  
Dr. Neergaards Vej 5F  
2970 Hørsholm  
Denmark

**Re: Evaxion Biotech A/S**  
**Registration Statement on Form F-1**  
**Filed July 7, 2022**  
**File No. 333-266050**

Dear Mr. Karmark:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at (202) 551-3635 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Dwight A. Kinsey, Esq.